#USA #New York #FDA #Pomerantz LLP #Unicycive Therapeutics

Pomerantz Law Firm Investigates Unicycive Therapeutics

Pomerantz LLP, a recognized leader in securities law, is taking steps to investigate claims on behalf of investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation stems from significant concerns over potential securities fraud and other business irregularities by the company and certain individuals associated with it.

On June 30, 2025, Unicycive made a troubling announcement. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) for OLC, a treatment aimed at addressing hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. The FDA's letter signaled that there had been issues noted at a third-party manufacturing vendor responsible for producing a key component of Unicycive's drug.

This critical information sparked immediate concern among investors. Following the disclosure, Unicycive's stock price plummeted by $2.03 per share, reflecting a staggering decrease of 29.85%, ending the day at a mere $4.77 per share. The swift decline raised alarms and prompted Pomerantz LLP's investigation, emphasizing the need for clarity regarding the company’s business practices and its executives' actions leading up to this significant financial drop.

Pomerantz LLP has substantial expertise in corporate and securities litigation, tracing its roots back to its founding by Abraham L. Pomerantz, who is often credited with being a pioneer in securities class actions. The firm has, over the years, consistently fought for victims of securities fraud, securing noteworthy settlements and awards to rectify the damages incurred by unjust business practices.

Investors of Unicycive are urged to pay close attention to this developing situation and are encouraged to reach out to Danielle Peyton at Pomerantz LLP for further details regarding the investigation or for guidance about potential participation in any class action that may arise. Investors can contact her at [email protected] or call 646-581-9980, ext. 7980 for assistance.

The firm is committed to uncovering the truth and protecting the rights of shareholders who may have been misled or harmed financially. They emphasize the importance of transparency in such significant matters and are dedicated to addressing any malfeasance associated with Unicycive’s conduct.

As this investigation unfolds, it serves as a stern reminder of the complexities and risks associated with investing in biotech firms, where regulatory approvals can dramatically shape market performance. Stakeholders in Unicycive should stay informed and vigilant as developments proceed in this high-stakes environment.